Hochschulschrift
Investigation of models with temporal and spatial interference in image based dosimetry of 177Lu-labelled radioligand therapies
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
München, Ludwig-Maximilians-Universität, Dissertation, 2016
- Keyword
-
Diagnose
Diagnostik
Differentialdiagnose
Pflegediagnose
- Event
-
Veröffentlichung
- (where)
-
München
- (who)
-
Universitätsbibliothek der Ludwig-Maximilians-Universität
- (when)
-
2016
- Creator
- Contributor
-
Böning, Guido
- URN
-
urn:nbn:de:bvb:19-197144
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:47 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Object type
- Hochschulschrift
Associated
- Delker, Andreas
- Böning, Guido
- Universitätsbibliothek der Ludwig-Maximilians-Universität
Time of origin
- 2016
Other Objects (12)
Influence of sampling schedules on dosimetry in radioligand therapies
EANM dosimetry committee recommendations for dosimetry of 177Lu-labelled somatostatin-receptor- and PSMA-targeting ligands
Comparison of different methods for post-therapeutic dosimetry in [177Lu]Lu-PSMA-617 radioligand therapy
Long-term nephrotoxicity of 177Lu-PSMA radioligand therapy
Influence of sampling schedules on [177Lu]Lu-PSMA dosimetry
Towards personalized internal radionuclide therapies with 90Y SIRT and 177Lu-PSMA: an investigation of 3D image based dosimetry
Joint EANM/SNMMI procedure guideline for the use of 177Lu-labeled PSMA-targeted radioligand-therapy (177Lu-PSMA-RLT)
Joint EANM/SNMMI procedure guideline for the use of 177Lu-labeled PSMA-targeted radioligand-therapy (177Lu-PSMA-RLT)
Individualised 177Lu-DOTATATE treatment of neuroendocrine tumours based on kidney dosimetry
Radioligand therapies in cancer: mapping the educational landscape in Europe
Bone marrow impairment during early [177Lu]PSMA-617 radioligand therapy: Haematotoxicity or tumour progression?
A comparison of simplified protocols of personalized dosimetry in NEN patients treated by radioligand therapy (RLT) with [177Lu]Lu-DOTATATE to favor its use in clinical practice
Influence of sampling schedules on dosimetry in radioligand therapies
EANM dosimetry committee recommendations for dosimetry of 177Lu-labelled somatostatin-receptor- and PSMA-targeting ligands
Comparison of different methods for post-therapeutic dosimetry in [177Lu]Lu-PSMA-617 radioligand therapy
Long-term nephrotoxicity of 177Lu-PSMA radioligand therapy
Influence of sampling schedules on [177Lu]Lu-PSMA dosimetry
Towards personalized internal radionuclide therapies with 90Y SIRT and 177Lu-PSMA: an investigation of 3D image based dosimetry
Joint EANM/SNMMI procedure guideline for the use of 177Lu-labeled PSMA-targeted radioligand-therapy (177Lu-PSMA-RLT)
Joint EANM/SNMMI procedure guideline for the use of 177Lu-labeled PSMA-targeted radioligand-therapy (177Lu-PSMA-RLT)
Individualised 177Lu-DOTATATE treatment of neuroendocrine tumours based on kidney dosimetry
Radioligand therapies in cancer: mapping the educational landscape in Europe
Bone marrow impairment during early [177Lu]PSMA-617 radioligand therapy: Haematotoxicity or tumour progression?
A comparison of simplified protocols of personalized dosimetry in NEN patients treated by radioligand therapy (RLT) with [177Lu]Lu-DOTATATE to favor its use in clinical practice
Influence of sampling schedules on dosimetry in radioligand therapies
EANM dosimetry committee recommendations for dosimetry of 177Lu-labelled somatostatin-receptor- and PSMA-targeting ligands
Comparison of different methods for post-therapeutic dosimetry in [177Lu]Lu-PSMA-617 radioligand therapy
Long-term nephrotoxicity of 177Lu-PSMA radioligand therapy
Influence of sampling schedules on [177Lu]Lu-PSMA dosimetry
Towards personalized internal radionuclide therapies with 90Y SIRT and 177Lu-PSMA: an investigation of 3D image based dosimetry
Joint EANM/SNMMI procedure guideline for the use of 177Lu-labeled PSMA-targeted radioligand-therapy (177Lu-PSMA-RLT)
Joint EANM/SNMMI procedure guideline for the use of 177Lu-labeled PSMA-targeted radioligand-therapy (177Lu-PSMA-RLT)
Individualised 177Lu-DOTATATE treatment of neuroendocrine tumours based on kidney dosimetry
Radioligand therapies in cancer: mapping the educational landscape in Europe
Bone marrow impairment during early [177Lu]PSMA-617 radioligand therapy: Haematotoxicity or tumour progression?